Compare ESCA & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESCA | TTRX |
|---|---|---|
| Founded | 1922 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 257.2M | 281.2M |
| IPO Year | 1995 | 2025 |
| Metric | ESCA | TTRX |
|---|---|---|
| Price | $20.13 | $9.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 44.0K | ★ 70.7K |
| Earning Date | 04-30-2026 | 05-31-2026 |
| Dividend Yield | ★ 3.50% | N/A |
| EPS Growth | ★ 6.45 | N/A |
| EPS | ★ 1.00 | N/A |
| Revenue | ★ $180,541,000.00 | N/A |
| Revenue This Year | $4.15 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.82 | ★ N/A |
| Revenue Growth | ★ 2.71 | N/A |
| 52 Week Low | $11.41 | $2.57 |
| 52 Week High | $23.07 | $11.69 |
| Indicator | ESCA | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.44 | 56.29 |
| Support Level | $17.63 | $2.95 |
| Resistance Level | $21.32 | $10.48 |
| Average True Range (ATR) | 1.12 | 0.85 |
| MACD | -0.11 | 0.02 |
| Stochastic Oscillator | 36.53 | 68.38 |
Escalade Inc manufactures and distributes sporting goods for a varied range of activities. These sports include archery, table tennis, basketball goals, trampoline, play systems, fitness, game tables like hockey and soccer, billiards, darting, and other outdoor games. These products are sold under the brand names like Goalrilla, Goalsetter, Woodplay, Silverback, Nodor, Rage, Child Life, among others. The geographic segments in which the company operates are the United States, Canada, Australia, and Other regions.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.